Do androgen deprivation and the biologically equivalent dose matter in low‐dose‐rate brachytherapy for intermediate‐risk prostate cancer?

por Tabata, Ryuji, Kimura, Takahiro, Kuruma, Hidetoshi, Sasaki, Hiroshi, Kido, Masahito, Miki, Kenta, Takahashi, Hiroyuki, Aoki, Manabu, Egawa, Shin
Publicado 2016

Comparison of neoadjuvant chemohormonal therapy vs. extended pelvic lymph-node dissection in high-risk prostate cancer treated with robot-assisted radical prostatectomy

por Oishi, Takuya, Hatakeyama, Shingo, Tabata, Ryuji, Fujimori, Daiji, Fukuda, Mamoru, Shinozaki, Tetsuo, Ishii, Noritaka, Iwamura, Hiromichi, Okamoto, Teppei, Yamamoto, Hayato, Yoneyama, Takahiro, Hashimoto, Yasuhiro, Sato, Satoshi, Ohyama, Chikara
Publicado 2023

Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma

por Numakura, Kazuyuki, Sekine, Yuya, Hatakeyama, Shingo, Muto, Yumina, Sobu, Ryuta, Kobayashi, Mizuki, Sasagawa, Hajime, Kashima, Soki, Yamamto, Ryohei, Nara, Taketoshi, Akashi, Hideo, Tabata, Ryuji, Sato, Satoshi, Saito, Mitsuru, Narita, Shintaro, Ohyama, Chikara, Habuchi, Tomonori
Publicado 2023